Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus Chidamide in Newly Diagnosed ENKTL
NCT04994210Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and tucidinostat in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Sun Yat-sen University. Primary endpoints: Objective Response Rate at 24 months, Complete Response Rate at 24 months and 1 more. Status: unknown.
02
Drugs
sintilimabtucidinostat
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT04994210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994210.